Preclinical Efficacy of Anecortave Acetate

Survey of Ophthalmology

Volumn 52, Issue 1 SUPPL., 2007, Pages

  Clark, Abbot F ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

age related macular degeneration; anecortave acetate; choroidal neovascularization; efficacy; preclinical

Indexed keywords

AL 42129; AL 4940; ANECORTAVE; ANECORTAVE DESACETATE; ANGIOGENESIS INHIBITOR; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; INTRAOCULAR TUMOR; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINOPATHY; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; MACULAR DEGENERATION; NEOPLASMS; PREGNADIENEDIOLS; TREATMENT OUTCOME;

EID: 33846250377     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2006.11.004     Document Type: Article

References (37)

1. BenEzra D., Griffin B.W., Maftzir G., et al. Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 38 (1997) 1954-1962
2. Brooks P.C., Silletti S., von Schalscha T.L., et al. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92 (1998) 391-400
3. Ciulla T.A., Criswell M.H., Danis R.P., et al. Squalamine lactate reduces choroidal neovascularization in a laser-injury model in the rat. Retina 23 (2003) 808-814
4. Ciulla T.A., Walker J.D., Fong D.S., et al. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol 15 (2004) 211-220
5. Clark A. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol 52 Suppl 1 (2007) S26-S34
6. Clark A.F. AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs 6 (1997) 1867-1877
7. Clark A.F., Mellon J., Li X.Y., et al. Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Invest Ophthalmol Vis Sci 40 (1999) 2158-2162
8. Crum R., Szabo S., and Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230 (1985) 1375-1378
9. Dahlin D.C., and Rahimy M.H. Pharmacokinetics and metabolism of anecortave acetate in animals and humans. Surv Ophthalmol 52 Suppl 1 (2007) S49-S61
10. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 110 (2003) 2372-2383 discussion 2384-5
11. D'Amico D.J., Goldberg M.F., Hudson H., et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 23 (2003) 14-23
12. DeFaller J.M., and Clark A.F. A new pharmacological treatment for angiogenesis. In: Taylor H.R. (Ed). Pterygium (2000), Kugler Publications, The Hague, The Netherlands 159-181
13. Dobi E.T., Puliafito C.A., and Destro M. A new model of experimental choroidal neovascularization in the rat. Arch Ophthalmol 107 (1989) 264-269
14. Dorrell M., Uusitalo-Jarvinen H., Aguilar E., and Friedlander M. Ocular neovascularization: Basic mechanisms and therapeutic advances. Surv Ophthalmol 52 Suppl 1 (2007) S3-S19
15. Folkman J. A novel anti-vascular therapy for cancer. Cancer Biol Ther 3 (2004) 338-339
16. Folkman J. Angiogenesis inhibitors: a new class of drugs. Cancer Biol Ther 2 (2003) S127-S133
17. Fotsis T., Zhang Y., Pepper M.S., et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368 (1994) 237-239
18. Friedman D.S., O'Colmain B.J., Muñoz B., et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122 (2004) 564-572
19. Genaidy M., Kazi A.A., Peyman G.A., et al. Effect of squalamine on iris neovascularization in monkeys. Retina 22 (2002) 772-778
20. Haynes W.L., Proia A.D., and Klintworth G.K. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci 30 (1989) 1588-1593
21. Heaton J., Kastner P., and Hackett R. Preclinical safety of anecortave acetate. Surv Ophthalmol 52 Suppl 1 (2007) S35-S40
22. Kenyon B.M., Voest E.E., Chen C.C., et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 37 (1996) 1625-1632
23. Kimura H., Sakamoto T., Hinton D.R., et al. A new model of subretinal neovascularization in the rabbit. Invest Ophthalmol Vis Sci 36 (1995) 2110-2119
24. Li W.W., Casey R., Gonzalez E.M., et al. Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest Ophthalmol Vis Sci 32 (1991) 2898-2905
25. McNatt L.G., Lane D., and Clark A.F. Angiostatic activity and metabolism of cortisol in the chorioallantoic membrane (CAM) of the chick embryo. J Steroid Biochem Mol Biol 42 (1992) 687-693
26. McNatt L.G., Weimer L., Yanni J., et al. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther 15 (1999) 413-423
27. Moss S.E., Klein R., and Klein B.E. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105 (1998) 998-1003
28. Otani A., Slike B.M., Dorrell M.I., et al. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci USA 99 (2002) 178-183
29. Penn J.S., Henry M.M., and Tolman B.L. Exposure to alternating hypoxia and hyperoxia causes severe proliferative retinopathy in the newborn rat. Pediatr Res 36 (1994) 724-731
30. Penn J.S., Rajaratnam V.S., Collier R.J., et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 42 (2001) 283-290
31. Phelps D.L., and Rosenbaum A.L. Vitamin E in kitten oxygen-induced retinopathy. II. Blockage of vitreal neovascularization. Arch Ophthalmol 97 (1979) 1522-1526
32. Proia A.D., Hirakata A., McInnes J.S., et al. The effect of angiostatic steroids and beta-cyclodextrin tetradecasulfate on corneal neovascularization in the rat. Exp Eye Res 57 (1993) 693-698
33. Russell S.R., Hudson H.L., Jerdan J.A., et al. Anecortave acetate for the treatment of exudative age-related macular degeneration-A review of clinical outcomes. Surv Ophthalmol 52 Suppl 1 (2007) S79-S90
34. Schmidt-Erfurth U., Michels S., Michels R., et al. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 15 (2005) 482-485
35. Smith L.E., Wesolowski E., McLellan A., et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35 (1994) 101-111
36. Tobe T., Ortega S., Luna J.D., et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153 (1998) 1641-1646
37. Wang Y.S., Friedrichs U., Eichler W., et al. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol 240 (2002) 42-48